Home › Triple-Negative Breast Cancer › Rhode Island
Triple-Negative Breast Cancer clinical trials in Rhode Island
5 studies for Triple-Negative Breast Cancer are looking for participants at sites in Rhode Island.
Cities in Rhode Island
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Providence Health, Providence
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693, Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 24, 2025 · NCT06974604From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.